Targeting the allergen-specific CD4+ T cell - Strategies for improved allergen immunotherapy

Allergy and Clinical Immunology International

Volumn 13, Issue 4, 2001, Pages 170-177

  Rolland, J ^a   O'Hehir, R E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALLERGEN; CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INSECT VENOM; INTERLEUKIN 4; LIGAND; PEPTIDE;

ALLERGIC DISEASE; ALLERGY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BINDING SITE; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; CELL TYPE; CLONAL ANERGY; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MAST CELL; OUTCOMES RESEARCH; T LYMPHOCYTE;

EID: 0034904891     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
2. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
3. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects
4. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes
5. Bee venom immunotherapy induces a shift in cytokine responses from a Th-2 to a Th-1 dominant pattern: Comparison of rush and conventional immunotherapy
6. 2-derived peptides by conventional bee venom immunotherapy
7. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
8. Long-term analysis of allergen-specific T cell clones from patients with asthma treated with allergen rush immunotherapy
9. + T cells during conventional allergen immunotherapy
10. 1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen
11. + T cells from allergic individuals
12. Decrease of allergen-specific T-cell response induced by local nasal immunotherapy
13. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γ and IL-4 expression by circulating T lymphocytes
14. The specificity and regulation of T-cell responsiveness to allergens
15. Th1-Th2 cells in allergic responses: At the limits of a concept
16. Allergen-driven limiting dilution analysis of human IL-4 and IFN-γ production in allergic rhinitis and clinically tolerant individuals
17. Allergen immunotherapy: Anergy, deletion and immune deviation
18. Cytokines: Principles and prospects
19. The biological function of allergens: Relevant for the induction of allergic diseases?
20. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response
21. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom
22. How MHC class II molecules acquire peptide cargo: Biosynthesis and trafficking through the endocytic pathway
23. House dust mite allergy: From T-cell epitopes to immunotherapy
24. HLA supertypes and supermotifs: A functional perspective on HLA polymorphism
25. T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope
26. Relationships among TcR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells
27. + T cells
28. Regulation of cytokine production by human Th0 cells following stimulation with peptide analogues: Differential expression of TGF-β in activation and anergy
29. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
30. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: A role for intramolecular epitope suppression
31. Induction of tolerance via the respiratory mucosa
32. Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes
33. + T cell responses: The alternative approach
34. The distribution of dust mite allergen in the houses of patients with asthma
35. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells
36. + T cells
37. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy
38. Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes
39. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin
40. Peripheral deletion of antigen-reactive T cells in oral tolerance
41. Aerosolized antigen exposure without adjuvant causes increased IgE production and increased airway responsiveness in the mouse
42. Regulation of murine lymphokine production in vivo
43. + T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics
44. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma
45. Regulation of immune responses at mucosal surfaces: Allergic respiratory disease as a paradigm
46. Activation of naive, memory and effector T cells
47. Regulation of CTLA-4 expression during T cell activation
48. +) T cells
49. CTLA-4 is required for the induction of high dose oral tolerance
50. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
51. Development of murine allergic asthma is dependent upon B7-2 costimulation
52. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function
53. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T cell help via APC activation
54. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production
55. Reversal of human allergic T helper 2 responses by engagement of signaling lymphocytic activation molecule
56. + T cell differentiation
57. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells
58. + T cells
59. An epitope delivery system for use with recombinant mycobacteria
60. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity
61. Reciprocal control of T helper cell and dendritic cell differentiation
62. Homing of naive, memory and effector lymphocytes
63. Lymphocyte homing and homeostasis
64. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
65. The chemokine system: Redundancy for robust outputs